{
    "Trade/Device Name(s)": [
        "Innovita HCG Pregnancy Rapid Combo Test"
    ],
    "Submitter Information": "INNOVITA (Tangshan) Biological Technology Co., Ltd.",
    "510(k) Number": "K241919",
    "Predicate Device Reference 510(k) Number(s)": [
        "K203272"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "JHI"
    ],
    "Summary Letter Date": "August 2, 2024",
    "Summary Letter Received Date": "July 1, 2024",
    "Submission Date": "July 30, 2024",
    "Regulation Number(s)": [
        "21 CFR 862.1155"
    ],
    "Regulation Name(s)": [
        "Human chorionic gonadotropin (HCG) test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Human chorionic gonadotropin (HCG)"
    ],
    "Specimen Type(s)": [
        "Urine",
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Lateral flow immunochromatographic assay",
        "Colloidal gold detection"
    ],
    "Methodologies": [
        "Immunochromatographic",
        "Double antibody sandwich"
    ],
    "Submission Type(s)": [
        "Test",
        "Assay",
        "Cassette"
    ],
    "Document Summary": "FDA 510(k) summary for Innovita HCG Pregnancy Rapid Combo Test, a lateral flow immunochromatographic assay for qualitative detection of HCG in urine and serum.",
    "Indications for Use Summary": "Qualitative detection of human chorionic gonadotropin in urine or serum to aid in early pregnancy detection for use by health care professionals including at point of care.",
    "fda_folder": "Clinical Chemistry"
}